Please assess the completion status of the following clinical trial:

Trial Title: Safety, Immunogenicity and Efficacy of R21 Matrix-M in 5-17 Month Old Children in Nanoro, Burkina Faso

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy child aged 5-17 months at the time of first study vaccination~* Provide written Informed consent of parent/guardian~* Child and parent/guardian resident in the study area villages and anticipated to be available for vaccination and follow-up for 2 years following last dose of vaccination~Exclusion Criteria:~* Clinically significant skin disorder (psoriasis, contact dermatitis etc.), immunodeficiency, cardiovascular disease, respiratory disease, endocrine disorder, liver disease, renal disease, gastrointestinal disease, neurological illness.~* Weight-for-age Z score of less than -3 or other clinical signs of malnutrition.~* History of allergic reaction, significant IgE-mediated event, or anaphylaxis to immunisation.~* History of allergic disease or reactions likely to be exacerbated by any component of the vaccines, e.g. neomycin.~* Sickle cell disease.~* Clinically significant laboratory abnormality as judged by the study clinician.~* Blood transfusion within one month of enrolment.~* Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate.~* Previous vaccination with experimental malaria vaccines.~* Participation in another research study involving receipt of an investigational product in the 30 days preceding enrolment, or planned use during the study period.~* Current participation in another clinical trial, or within 12 weeks of this study.~* Known maternal HIV infection (No testing will be done by the study team).~* Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months (For corticosteroids, this will mean prednisone, or equivalent, \>= 0.5 mg/kg/day. Inhaled and topical steroids are allowed).~* Any significant disease, disorder or situation which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial.

- Gender: ALL
- Minimum Age: 5 Months
- Maximum Age: 17 Months
- Healthy Volunteers: t

Study Arms:
- Group 1 (Type: EXPERIMENTAL): n=150. Age 5-17 month-old. 5mcg R21/25mcg Matrix-M at Day 0, 28 and 56 and 1 year.~Following the initial booster, Group 1 will be randomised 2:1 into Groups1a and 1b for 5ug R21/50ug Matrix-M: control. Groups 1a and 1b will receive these second and third booster vaccinations each year prior to the malaria season
- Group 2 (Type: EXPERIMENTAL): n=150. Age 5-17 month-old. 5mcg R21/50mcg Matrix-M at Day 0, 28 and 56 and 1 year.~Following the initial booster, Group 2 will be randomised 2:1 into Groups 2a and 2b or 5ug R21/50ug Matrix-M:ccontrol. Groups 2a and 2b will receive these second and third booster vaccinations each year prior to the malaria season
- Group 3 (control group) (Type: PLACEBO_COMPARATOR): n=150. Age 5-17 month-old. Rabies Vaccine by the end of the trial.

Based on this trial design, predict the completion outcome and termination type (if applicable).